Company intelligence / Profile preview

Litha Healthcare Group

Midrand, Gauteng, South Africa

Ownership: Private
Employees: ~475
Development stage: Other

Overview

Litha Healthcare Group's commercial portfolio covers nearly 100 molecules (primarily in primary care) and specialty generic drugs; pipeline included 124 products expected to launch over five years starting from acquisition by Acino in 2017.

Therapeutic areas: OtherNeurologyDermatologyInfectious DiseasesGastroenterologyOncologyMen's HealthOphthalmology
Modalities: Small moleculeBiologicVaccineMedical devicesComplementary medicines
Industry: Biotech

Partnerships

International pharmaceutical and medical companiesGovernment partnerships including The Biovac Institute

Beyond the preview

Go deeper on Litha Healthcare Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Litha Healthcare Group.

Explore the full profile